Advertisement. This article was created in paid cooperation with Mavericks Genetics. Selection, classification, and evaluation of information remain with Hemp Magazine.
A California breeder emerging from commercial clone production who sees himself as a plant breeding company rather than a cannabis brand. What drives this approach, and why the announced move to triploid varieties is the most interesting part of the story.
Mavericks Genetics was founded in California in 2022. According to the company, it emerged from one of the world’s largest operations for clones and genetics serving large-scale production. The idea: to bring the knowledge from supplying commercial producers into the consumer market and make contemporary California genetics accessible to a broader audience. For the European market, this represents a different origin story than most seed suppliers operating here.
The Claim: Plant Breeding Over Brand Building
CEO Pablo Gómez describes his approach to breeding philosophy as closer to a company focused on plant intellectual property and industrial production than a classical cannabis brand. The focus lies on research, selection, validation, and reproducibility—with the goal of delivering varieties whose characteristics are backed by data.
This is self-description first, and it’s difficult to verify from the outside. Yet it’s interesting because it describes a real shift happening in the seed market. Where the reputation of individual phenotypes and breeder narratives once dominated, measurable metrics increasingly take center stage: germination rates, feminization rates, stability across generations, documented cannabinoid and terpene profiles. Coming from commercial supply chains brings this mindset along, because there, inconsistent batches have immediate financial consequences.
The company highlights Tropicana Cherry, Cherry Runtz, and Kiwi Papaya as flagship varieties. Gómez describes the target customer as someone with discerning taste who values distinctive flavors and quality. This is positioning, not a product specification—it differentiates the supplier from the mass market segment, where price and germination guarantees dominate.
Triploid Varieties: The Actually Compelling Part
Asked about next steps, the company mentions launching an F1 line and additional triploid varieties. The latter deserves explanation, as it remains relatively uncommon in the home grower space.
Cannabis is normally diploid—it possesses two chromosome sets. Triploid plants have three. They arise when a tetraploid plant is crossed with a diploid. The odd chromosome set cannot divide cleanly during cell division, making such plants largely sterile and setting few seeds. This principle has been known for decades in fruit and vegetable breeding; seedless watermelons and many banana varieties rely on it.
For growers, the practical appeal is protection against unwanted pollination. A single overlooked male plant or incoming pollen can ruin a flower crop, as the plant invests energy in seed production instead of buds. With largely sterile plants, this risk diminishes. Manufacturers also point to higher yields and increased resin production.
On this second claim, caution is warranted. Research on triploid cannabis is still emerging, published trials are limited, and yield results vary depending on variety and growing conditions. Reduced seed production is confirmed; a blanket yield advantage is not. Mavericks offers verification of triploidy for their triploid varieties, which makes sense in this segment—you can’t tell by looking at a plant how many chromosome sets it has.
What Data the Company Provides
On quality assurance, Gómez points to data on stability, feminization, and germination rates, plus terpene and cannabinoid analyses made available on request for individual varieties. For buyers, this is the verifiable part of the promise—it’s worth asking for. An analysis certificate tied to a specific batch says more than a variety description alone.
However, the same applies to any lab report: it refers to the tested sample, not the plant that ultimately stands in your grow tent. Cannabinoid levels depend heavily on growing conditions, harvest timing, and processing. A variety specification describes potential under good conditions, not a guarantee.
The European Market Outlook
On developments in Germany and Europe, the company expresses the expected optimism, seeing its contribution in bringing California genetics to Europe. The market does show receptiveness to this. At the same time, the legal framework here differs from California and determines what from any lineup is actually accessible.
A Brief Note on Legal Status
In Germany, adults can grow up to three cannabis plants for personal consumption under the Cannabis Consumption Act and obtain seeds for this purpose. What matters legally is always the law of the cultivation location, not the shipping country. Rules vary considerably across Europe; in Austria, for instance, seed sales are legal, but it becomes punishable once THC-containing plant material is produced. Anyone ordering should know the regulations at their own location.
Note: This article reflects the status as of October 15, 2026, and is not legal advice. Information about the company, product range, and services comes from Mavericks Genetics and has not been independently verified by us. Cannabis cultivation and possession are restricted to adults and bound by applicable regulations in each jurisdiction.
Hast du schon mal von triploiden Cannabissorten gehört?
Sources: Written statement from Pablo Gómez, CEO Mavericks Genetics, October 14, 2026; Cannabis Consumption Act (KCanG); Austrian Narcotics Act; independent research on polyploidy in plant breeding.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
